PTC THERAPEUTICS INC (PTCT)
Health Care · Biotechnology · NASDAQ
A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases.
What PTC THERAPEUTICS INC does
PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare disorders. The company’s portfolio focuses on small molecule and gene therapy technologies targeting areas such as Duchenne muscular dystrophy, spinal muscular atrophy, and aromatic L-amino acid decarboxylase deficiency.
Themes: rare diseases, gene therapy, Duchenne muscular dystrophy, spinal muscular atrophy
Fundamentals
- Price$62.56 as of 2026-10-08 close
- Market cap$5.2B as of 2026-07-29 (share count; price 2026-10-08)
- 1-year return-3.0% 2025-10-08 close $64.48 → 2026-10-08 close $62.56
- P/En/a negative earnings
- Net margin+39.4% FY2025, SEC XBRL
- Debt / equity848.93 as of 2026-09-02
- Revenue growth (YoY)-42.8% as of 2026-09-02
- Revenue CAGR (3y)+35.3% SEC XBRL
- Beta0.93 as of 2026-09-02
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How PTCT compares in its sector
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PTC THERAPEUTICS INC looks technically
PTC THERAPEUTICS INC (PTCT) is trading 13.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 15 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 2.2% above its 52-week low (its lowest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 8% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 13.0% below its 200-day average, the long-term trend line — a long-term downtrend | -13.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $68.56 | $68.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $71.94 | $71.94 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 64.5675. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 15 trading days ago — a "death cross", a bearish long-term signal | 15 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($61.23 to $66.58) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 24.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $90.86 | $90.86 |
|---|---|---|
| From the 52-week high | it is 31.1% below its 52-week high (its highest price of the past year) | -31.1% |
| Above the 52-week low | it is 2.2% above its 52-week low (its lowest price of the past year) | +2.2% |
| Below the 52-week high | it is 31.1% below its highest point of the past year | 31.1% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $90.86 (set on 2026-07-09) | $90.86 |
| Given back of the 52-week move | over the past year its closes ranged ($62.28 to $89.55), and it has recovered essentially none of its fall from last year’s high — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $79.13 to $80.01. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.0% |
| From the all-time high | it is 31.1% below its all-time high | -31.1% |
| Nearest price level | it is trading 1.4% below a resistance level at $63.46 — a price it turned at three times since 2025-09-18, most recently on 2026-05-01. Since 2024-10-08 it has 9 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $4.03 (set on 2016-11-03) | $4.03 |
| Above the all-time low | it is 1452.4% above its all-time low | +1,452% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 8% of the past ~6 months), which often precedes a bigger move | 8th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.06 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.06 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $61.38 and $68.03 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $61.38 – $64.70 – $68.03 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 4.5 daily ranges below its 200-day average price (13.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.9% |
|---|---|---|
| Open gap | it gapped 3.7% below the previous close 48 sessions ago and has not traded back through the level it left behind at 75.52 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.7% |
| Gap filled | a 2.2% gap down opened on 2026-09-08 has been "filled" 22 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 22 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -1.79% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.1 percentage points (the stock lost 9.1% while the market gained 1.0%) | -10.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 33.2 percentage points (the stock lost 29.4% while the market gained 3.8%) | -33.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 26.7 percentage points (the stock lost 9.2% while the market gained 17.5%) | -26.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 18.0 percentage points (the stock lost 3.0% while the market gained 15.0%) | -18.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -11.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $72.80 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -14.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $67.97 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -8.0% |
Price levels it has turned at before
PTCT last closed at $62.56 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $63.46 | Resistance | 1.4% above the last close | turned there three times · 2025-09-18 to 2026-05-01 |
| $61.33 | Support | 2.0% below the last close | turned there twice · 2026-03-06 to 2026-09-24 |
| $64.62 | Resistance | 3.3% above the last close | turned there twice · 2026-02-20 to 2026-07-31 |
| $58.06 | Support | 7.2% below the last close | turned there twice · 2025-03-17 to 2025-09-25 |
| $67.53 | Resistance | 8.0% above the last close | turned there four times · 2025-10-03 to 2026-08-24 |
| $54.20 | Support | 13.4% below the last close | turned there twice · 2024-12-03 to 2025-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $64.57.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $64.48 and $64.57 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $61.23.
This reading has stood for 6 trading days, since 2026-10-01.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Near the 52-week low · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.71 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$101.79 range $70.00 – $137.00; median $101.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PTCT
- Consensus EPS estimate$0.38 next reporting period, as of 2026-10-04
- Estimate change, 30 days+$0.07 (+22.6%) from $0.31, on 2026-08-30, 35-day window
- Readings revised upward20% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on product revenue and royalty streams from a limited number of approved products.","High volatility in revenue due to significant fluctuations in collaboration and license income.","Substantial long-term financial liabilities, particularly those related to the sale of future royalties."]
What changed in the latest 10-Q
AI-assisted comparison of PTCT's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Annual Report filed February 19, 2026 (instead of 2024 Annual Report filed February 27, 2025)
- Newer filing adds 'Global Commercial Footprint' as subsection header
- Newer filing adds 'Global DMD Franchise' as subsection header
- Newer filing states Sephience approved by MHLW Japan in December 2025
- Newer filing states Sephience approved by ANVISA Brazil in February 2026
- Newer filing reports $124.6 million net sales of Sephience for Q1 2026
- Newer filing adds detailed narrative on Translarna EC negative opinion adoption in March 2025 and NDA withdrawal in February 2026
- Newer filing states Translarna Q1 2026 net sales of $59.0 million
- Newer filing states Emflaza Q1 2026 net sales of $21.5 million
- Newer filing adds discussion of Emflaza orphan drug exclusivity expiration in February 2024 and generic competition impact
- Newer filing states Emflaza's orphan drug exclusivity for patients 2-5 years expires June 2026
- Newer filing adds subsection on Upstaza/Kebilidi with FDA accelerated approval in November 2024
- Newer filing adds subsection on Tegsedi and Waylivra agreements and approvals
- Removed:
- Older filing references Risk Factors in both Part II Item 1A of the Quarterly Report and Part I Item 1A of 2024 Annual Report; newer filing references only Part I Item 1A of 2025 Annual Report
- Older filing includes 'Censa Rights Satisfaction Agreement' subsection with detailed transaction terms; newer filing does not include this section
- Reworded:
- Older filing: 'We believe that this allows us to maximize value for all of our stakeholders.' Newer filing removes this sentence
- Older filing: 'We have a diversified therapeutic portfolio pipeline' (includes 'pipeline'). Newer filing: 'We have a diversified therapeutic portfolio' (removes 'pipeline')
- Older filing orders Sephience approvals chronologically (June 2025 EC, July 28 2025 FDA). Newer filing reorders as: June 2025 EC, July 2025 FDA, December 2025 MHLW, February 2026 ANVISA
- Older filing: 'During the quarter ended September 30, 2025, we recognized $19.6 million in net sales of Sephience.' Newer filing: 'During the three months ended March 31, 2026, we recognized $124.6 million in net sales of Sephience.'
- Notes:
- Older filing text is truncated at 'aggrega'; full sentence not available for comparison
- Comparison reflects different reporting periods (Q3 2025 for older filing vs. Q1 2026 for newer filing)
Risk Factors
- Added:
- Newer filing references Form 10-K for year ended December 31, 2025 (instead of December 31, 2024 in older filing)
- Consolidated Balance Sheet as of March 31, 2026 added (newer filing shows Q1 2026 data vs. Q3 2025 data in older filing)
- Consolidated Balance Sheet as of December 31, 2025 added as comparison period (newer filing)
- Consolidated Statements of Operations for three months ended March 31, 2026 added
- Consolidated Statements of Operations for three months ended March 31, 2025 added for comparison
- Consolidated Statements of Comprehensive Loss/Income for three months ended March 31, 2026 and 2025 added
- Consolidated Statements of Stockholders' Deficit for three months ended March 31, 2026 added
- Consolidated Statements of Stockholders' Deficit for three months ended March 31, 2025 added for comparison
- Removed:
- Consolidated Balance Sheet as of September 30, 2025 removed (older filing showed Q3 2025)
- Consolidated Balance Sheet as of December 31, 2024 removed (older filing comparison date)
- Consolidated Statements of Operations for three months ended September 30, 2025 and 2024 removed
- Consolidated Statements of Operations for nine months ended September 30, 2025 and 2024 removed
- Consolidated Statements of Comprehensive Income (Loss) for three and nine months ended September 30, 2025 and 2024 removed
- Consolidated Statements of Stockholders' Deficit for three months ended September 30, 2025 removed
- Reworded:
- Risk Factors Item 1A now references 'Annual Report on Form 10-K for the year ended December 31, 2025' instead of 'December 31, 2024'
- Notes:
- The comparison is between Q1 2026 10-Q filing (newer) and Q3 2025 10-Q filing (older), representing different reporting periods
- Financial statements sections are substantially different due to different quarterly reporting dates (March 31, 2026 vs. September 30, 2025)
- The older filing text appears truncated at the end of the Stockholders' Deficit table, limiting completeness of comparison for that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 23 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 8 sells ($3M) — 3 selling insiders
- Last 90 days · read to 2026-10-040 buys · 23 sells ($8M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 71 sells ($25M) — 9 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-06. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PTCT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PTCT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 22,218,911
- Reported value $1,812,396,627
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PTCT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PTCT had 9,738,919 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PTCT had 11.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.03 days to cover at the same settlement.
- Reported short interest (shares) 9,738,919
- Short interest (% of shares outstanding) 11.7%
- Prior settlement (shares) 9,828,154
- Reported change -0.91%
- Days to cover (reported) 11.03
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PTCT vs…
PTC THERAPEUTICS INC is found in…
Frequently asked questions
What does PTC THERAPEUTICS INC (PTCT) do?
PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare disorders. The company’s portfolio focuses on small molecule and gene therapy technologies targeting areas such as Duchenne muscular dystrophy, spinal muscular atrophy, and aromatic L-amino acid decarboxylase deficiency.
What sector is PTC THERAPEUTICS INC (PTCT) in?
PTC THERAPEUTICS INC (PTCT) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are PTC THERAPEUTICS INC's (PTCT) competitors?
Notable peers of PTC THERAPEUTICS INC (PTCT) include Biogen, Sarepta Therapeutics, Novartis, Roche and Eli Lilly. This peer set is informational only — not financial advice.
Is PTC THERAPEUTICS INC (PTCT) overbought or oversold right now?
PTC THERAPEUTICS INC (PTCT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PTCT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.